Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42160443 for postherpetic neuralgia and post-traumatic neuralgia
NL-OMON35401Phase 2Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fulranumab in postherpetic neuralgia (PHN) and post-traumatic neuralgia (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in average pain intensity. Planned start Sep 2009; status: withdrawn.
02
Drugs
fulranumab
03
Conditions
postherpetic neuralgia (PHN)post-traumatic neuralgia
Beyond the preview
Go deeper on NL-OMON35401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35401.